구조모아 (StructureMoa)항암 chemical structure spider web
방문JohnsonJohnson
분석
큐레이션 브리핑
경쟁 포지션: Class-defining BCMA engager; competes with Elrexfio and BCMA CAR-T.
기전. Simultaneously engages BCMA on plasma cells and CD3 on T cells, forming an immune synapse that redirects polyclonal T cells to lyse BCMA+ myeloma cells independent of TCR specificity.
우선 정리한 핵심 프로그램입니다. 공개 출처가 있는 필드만 표시합니다.
구조화 데이터
BCMA × CD3
Relapsed or refractory multiple myeloma
US, EU, JP
Approved
tecvayli · teclistamab · Tecvayli · JNJ-64007957 · teclistamab-cqyv
2026-09-10
Data Confidence · High
Development Signal · Established
IgG4 bispecific T-cell engager (DuoBody)
Controlled Fab-arm exchange creating one BCMA arm and one CD3 arm, silenced Fc
No manufacturing slot needed, so it can be started immediately in rapidly progressing myeloma.
구조화 데이터
No manufacturing slot needed, so it can be started immediately in rapidly progressing myeloma.
BCMA loss, soluble BCMA acting as a sink, and T-cell exhaustion.
IgG4 bispecific T-cell engager (DuoBody)
BCMA × CD3 · BCMA expression, MRD negativity, serum free light chain response.
CRS and ICANS mitigation during step-up; infection prophylaxis and IVIG support
Class-defining BCMA engager; competes with Elrexfio and BCMA CAR-T.
R/R myeloma after ≥4 prior lines including a PI, an IMiD, and an anti-CD38 antibody
5L+ (label), earlier in practice and ongoing trials
Subcutaneous with step-up dosing
Weekly, with biweekly option after sustained response
ORR ~63% in MajesTEC-1
CRS and ICANS mitigation during step-up; infection prophylaxis and IVIG support
Class-defining BCMA engager; competes with Elrexfio and BCMA CAR-T.
Simultaneously engages BCMA on plasma cells and CD3 on T cells, forming an immune synapse that redirects polyclonal T cells to lyse BCMA+ myeloma cells independent of TCR specificity.
T-cell activation and cytokine release, largely confined to step-up dosing.
Granzyme/perforin-mediated killing of BCMA+ plasma cells.
BCMA expression, MRD negativity, serum free light chain response.
BCMA loss, soluble BCMA acting as a sink, and T-cell exhaustion.
구조화 데이터
Human, cynomolgus
~2–3 weeks at steady state
T-cell activation markers, cytokine profile, soluble BCMA
구조화 데이터
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다. 효능 수치는 선택한 등록 결과이며 전적응증 값이 아닙니다.
구조화 데이터
ClinicalTrials.gov에 등록된 완료 예정일입니다. 추정이며 결과 발표를 단정하지 않습니다.
FDA accelerated approval
APPROVAL · 2022년 10월
Biweekly dosing option added to label
APPROVAL · 2024년 2월
바이오정보모아는 연구·교육용 과학·의약품 개발 정보입니다. 진료, 진단, 치료 지침, 규제 자문이 아닙니다.
JohnsonJohnson
분석
큐레이션 브리핑
경쟁 포지션: Class-defining BCMA engager; competes with Elrexfio and BCMA CAR-T.
기전. Simultaneously engages BCMA on plasma cells and CD3 on T cells, forming an immune synapse that redirects polyclonal T cells to lyse BCMA+ myeloma cells independent of TCR specificity.
우선 정리한 핵심 프로그램입니다. 공개 출처가 있는 필드만 표시합니다.
구조화 데이터
BCMA × CD3
Relapsed or refractory multiple myeloma
US, EU, JP
Approved
tecvayli · teclistamab · Tecvayli · JNJ-64007957 · teclistamab-cqyv
2026-09-10
Data Confidence · High
Development Signal · Established
IgG4 bispecific T-cell engager (DuoBody)
Controlled Fab-arm exchange creating one BCMA arm and one CD3 arm, silenced Fc
No manufacturing slot needed, so it can be started immediately in rapidly progressing myeloma.
구조화 데이터
No manufacturing slot needed, so it can be started immediately in rapidly progressing myeloma.
BCMA loss, soluble BCMA acting as a sink, and T-cell exhaustion.
IgG4 bispecific T-cell engager (DuoBody)
BCMA × CD3 · BCMA expression, MRD negativity, serum free light chain response.
CRS and ICANS mitigation during step-up; infection prophylaxis and IVIG support
Class-defining BCMA engager; competes with Elrexfio and BCMA CAR-T.
R/R myeloma after ≥4 prior lines including a PI, an IMiD, and an anti-CD38 antibody
5L+ (label), earlier in practice and ongoing trials
Subcutaneous with step-up dosing
Weekly, with biweekly option after sustained response
ORR ~63% in MajesTEC-1
CRS and ICANS mitigation during step-up; infection prophylaxis and IVIG support
Class-defining BCMA engager; competes with Elrexfio and BCMA CAR-T.
Simultaneously engages BCMA on plasma cells and CD3 on T cells, forming an immune synapse that redirects polyclonal T cells to lyse BCMA+ myeloma cells independent of TCR specificity.
T-cell activation and cytokine release, largely confined to step-up dosing.
Granzyme/perforin-mediated killing of BCMA+ plasma cells.
BCMA expression, MRD negativity, serum free light chain response.
BCMA loss, soluble BCMA acting as a sink, and T-cell exhaustion.
구조화 데이터
Human, cynomolgus
~2–3 weeks at steady state
T-cell activation markers, cytokine profile, soluble BCMA
구조화 데이터
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다. 효능 수치는 선택한 등록 결과이며 전적응증 값이 아닙니다.
구조화 데이터
ClinicalTrials.gov에 등록된 완료 예정일입니다. 추정이며 결과 발표를 단정하지 않습니다.
FDA accelerated approval
APPROVAL · 2022년 10월
Biweekly dosing option added to label
APPROVAL · 2024년 2월
바이오정보모아는 연구·교육용 과학·의약품 개발 정보입니다. 진료, 진단, 치료 지침, 규제 자문이 아닙니다.